Vaccine Adjuvants: Key Tools for Innovative Vaccine Design

被引:52
作者
Riese, Peggy [1 ]
Schulze, Kai [1 ]
Ebensen, Thomas [1 ]
Prochnow, Blair [1 ]
Guzman, Carlos A. [1 ]
机构
[1] Helmholtz Ctr Infect Res, Dept Vaccinol & Appl Microbiol, D-38124 Braunschweig, Germany
关键词
Adjuvants; adjuvant combinations; adjuvant licensing; delivery systems; limitations; regulatory aspects; vaccines; parenteral vaccination; mucosal vaccination; T-CELL RESPONSES; CYCLIC-DI-GMP; HEPATITIS-B-VACCINE; IMMUNOSTIMULATORY PHOSPHOROTHIOATE OLIGONUCLEOTIDE; CPG-CONTAINING OLIGODEOXYNUCLEOTIDES; ACTIVE SPECIFIC IMMUNOTHERAPY; CUTANEOUS DENDRITIC CELLS; HUMORAL IMMUNE-RESPONSES; HEAT-LABILE ENTEROTOXIN; POTENT MUCOSAL ADJUVANT;
D O I
10.2174/15680266113136660183
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Vaccines represent the most efficient tool for preventing diseases caused by infectious pathogens. During the last century significant progress has been made in vaccine development, resulting in the eradication or control of several diseases. However, the emergence of new pathogens and the inadequate protection conferred by some existing vaccines render necessary new vaccination strategies. Newly arising immunization approaches, such as subunit vaccines and mucosal administration, make the use of novel adjuvants essential. However, only a limited number of adjuvants are available on the market. The present review is focused on vaccine adjuvants approved for human vaccines and promising candidates which are currently under development. In this regard, emerging immune stimulators and combinations are discussed, together with their strengths, limitations and regulatory framework.
引用
收藏
页码:2562 / 2580
页数:19
相关论文
共 234 条
  • [51] Novel vaccines and adjuvant systems - The utility of animal models for predicting immunogenicity in humans
    Davis, Heather L.
    [J]. HUMAN VACCINES, 2008, 4 (03): : 246 - 250
  • [52] Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
    Davis, ID
    Chen, WS
    Jackson, H
    Parente, P
    Shackleton, M
    Hopkins, W
    Chen, QY
    Dimopoulos, N
    Luke, T
    Murphy, R
    Scott, AM
    Maraskovsky, E
    McArthur, G
    MacGregor, D
    Sturrock, S
    Tai, TY
    Green, S
    Cuthbertson, A
    Maher, D
    Miloradovic, L
    Mitchell, SV
    Ritter, G
    Jungbluth, AA
    Chen, YT
    Gnjatic, S
    Hoffman, EW
    Old, LJ
    Cebon, JS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (29) : 10697 - 10702
  • [53] What are the limits of adjuvanticity?
    Del Giudice, G
    Podda, A
    Rappuoli, R
    [J]. VACCINE, 2001, 20 : S38 - S41
  • [54] Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59® adjuvant Results from a dose-finding clinical trial in older adults
    Della Cioppa, Giovanni
    Nicolay, Uwe
    Lindert, Kelly
    Leroux-Roels, Geert
    Clement, Frederic
    Castellino, Flora
    Galli, Grazia
    Groth, Nicola
    Del Giudice, Giuseppe
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (02) : 216 - 227
  • [55] AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity
    Didierlaurent, Arnaud M.
    Morel, Sandra
    Lockman, Laurence
    Giannini, Sandra L.
    Bisteau, Michel
    Carlsen, Harald
    Kielland, Anders
    Vosters, Olivier
    Vanderheyde, Nathalie
    Schiavetti, Francesca
    Larocque, Daniel
    Van Mechelen, Marcelle
    Garcon, Nathalie
    [J]. JOURNAL OF IMMUNOLOGY, 2009, 183 (10) : 6186 - 6197
  • [56] Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres
    Diwan, M
    Tafaghodi, M
    Samuel, J
    [J]. JOURNAL OF CONTROLLED RELEASE, 2002, 85 (1-3) : 247 - 262
  • [57] Imiquimod and resiquimod as novel immunomodulators
    Dockrell, DH
    Kinghorn, GR
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (06) : 751 - 755
  • [58] Adjuvants for cancer vaccines
    Dubensky, Thomas W., Jr.
    Reed, Steven G.
    [J]. SEMINARS IN IMMUNOLOGY, 2010, 22 (03) : 155 - 161
  • [59] ISCOMATRIX Adjuvant Combines Immune Activation with Antigen Delivery to Dendritic Cells In Vivo Leading to Effective Cross-Priming of CD8+ T Cells
    Duewell, Peter
    Kisser, Ulrich
    Heckelsmiller, Klaus
    Hoves, Sabine
    Stoitzner, Patrizia
    Koernig, Sandra
    Morelli, Adriana B.
    Clausen, Bjorn E.
    Dauer, Marc
    Eigler, Andreas
    Anz, David
    Bourquin, Carole
    Maraskovsky, Eugene
    Endres, Stefan
    Schnurr, Max
    [J]. JOURNAL OF IMMUNOLOGY, 2011, 187 (01) : 55 - 63
  • [60] A pegylated derivative of α-galactosylceramide exhibits improved biological properties
    Ebensen, Thomas
    Link, Claudia
    Riese, Peggy
    Schulze, Kai
    Morr, Michael
    Guzman, Carlos A.
    [J]. JOURNAL OF IMMUNOLOGY, 2007, 179 (04) : 2065 - 2073